Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp has demonstrated progress in its clinical trials, showcased by an improved correlation in the ABCLEAR32 population, indicating a strengthened precision medicine approach. The company is actively engaging with regulatory bodies, not only for Alzheimer’s disease but also for Parkinson's disease and rare conditions like Rett syndrome, highlighting its multi-indication strategy. The ongoing discussions with regulators signify an optimistic momentum that aligns Anavex's biomarker findings with clinical relevance, suggesting a path toward potential regulatory approvals and reinforcing a positive outlook for the company's future.

Bears say

Anavex Life Sciences Corp has recently decreased its probability of success for its therapeutic models, projecting a 50% chance for the U.S. and a mere 15% for the EU, which reflects significant concerns regarding its product pipeline viability. The company's decision to withdraw its EU marketing application for blarcamesine, due to unfavorable feedback from the European Medicines Agency, indicates potential regulatory challenges and uncertainties surrounding its clinical development strategies. Such negative developments, combined with the need for a strategic reset, suggest increased risks that could adversely impact investor confidence and future financial performance.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.